香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Seres Group Co., Ltd. 賽力斯集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9927） 海外監管公告 本公告乃根據《香港聯合交易所有限公司證券上市規則》第13.10B條而作出。 茲載列賽力斯集團股份有限公司在上海證券交易所網站刊登的以下公告，僅供參 閱。 1. 賽力斯集團股份有限公司關於提前歸還臨時補充流動資金的募集資金的公告 2. 賽力斯集團股份有限公司第五屆董事會第三十次會議決議公告 3. 賽力斯集團股份有限公司2025年度董事會審計委員會履職報告 4. 賽力斯集團股份有限公司2025年度獨立董事述職報告－黎明 5. 賽力斯集團股份有限公司2025年度獨立董事述職報告－李開國 6. 賽力斯集團股份有限公司2025年度獨立董事述職報告－張國林 7. 賽力斯集團股份有限公司2025年度獨立董事述職報告－景旭峰 8. 賽力斯集團股份有限公司2025年度獨立董事 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2026年3月30日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；職工 代表董事李承宗先生；非執行董事李家慶先生及萬璇女士；獨立非執行董事李麗 華女士、曾勁峰教授及余堅先生。 证券代码：300759 证券简称：康龙化成 公告编号：2026-010 康龙化成（北京） ...

山東晨鳴紙業集團股份有限公司 SHANDONG CHENMING PAPER HOLDINGS LIMITED* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 聯交易預計公告」、「二〇二五年度獨立董事述職報告（楊彪）」、「二〇二五年度獨 立董事述職報告（李志輝）」、「二〇二五年度獨立董事述職報告（尹美群）」、「二 〇二五年度獨立董事述職報告（孫劍非）」、「二〇二五年度獨立董事述職報告（張 志元）」、「二〇二五年度獨立董事述職報告（羅新華）」、「二〇二五年度獨立董事 述職報告（萬剛）」、「二〇二五年度獨立董事述職報告（孔鵬志）」、「內部審計制 度」、「董事、高級管理人員薪酬管理制度」、「關於2026年度董事、高級管理人員 薪酬方案的公告」、「關於購買董事及高級管理人員責任險的公告」、「關於計提資 產減值準備的公告」、「董事會關於2024年度內部控制審計報告非標意見涉及事項 影響已消除的專項說明」、「審計委員會對董事會關於2024年度內部控制審計報告 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因依賴該等內容而引致的任何損失承擔任何責任。 MUYUAN FOODS CO., LTD. 牧 原 食 品 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號: 2714） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，牧原食品股份有限公司（「本公司」）在巨 潮資訊網（www.cninfo.com.cn）刊發了以下公告。茲載列如下，僅供參閱。 中國，河南省南陽市，2026年3月27日 於本公告日期，本公司董事會成員包括：(i)執行董事秦英林先生、曹治年先生及楊瑞華 女士；(ii)非執行董事錢瑛女士及蘇黨林先生；及(iii)獨立非執行董事周明笙先生、閻磊 先生及馮根福先生。 牧原食品股份有限公司 关于董事会对独立董事独立性自查情况的专项报告 根据证监会《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》 《深圳证券交易所上市公司自律监管指引第 1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Bank of Qingdao Co., Ltd.* 青 島 銀 行 股 份 有 限 公 司 * （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （H股股份代號：3866） 海外監管公告 本公告乃根據《香港聯合交易所有限公司證券上市規則》第13.10B條作出。 以下文件已於深圳證券交易所網站刊登，僅供參閱： 青島銀行股份有限公司 - 1 - 1. 董事會決議公告 2. 2025年度非經營性資金佔用及其他關聯資金往來情況匯總表 3. 關於青島銀行股份有限公司2025年度非經營性資金佔用及其他關聯資金往來 情況的專項說明 4. 2025年度內部控制評價報告 5. 2025年度內部控制審計報告 6. 2025年度獨立非執行董事述職報告 7. 獨立董事對相關事項的獨立意見 8. 董事會關於獨立董事2025年度獨立性情況的專項意見 9. 2025年度審計報告 特此公告。 承董事 ...

Core Viewpoint - The company, Hainan Huluwa Pharmaceutical Group Co., Ltd., is facing a risk warning on its stock due to a negative internal control audit report for the fiscal year 2024, effective from April 30, 2025 [2][3]. Group 1: Risk Warning Implementation - The company's stock will be subject to a risk warning as per the Shanghai Stock Exchange rules due to the negative opinion in the internal control audit report [2][3]. - The company is required to disclose progress on the risk warning at least once a month during the warning period [2]. Group 2: Measures Taken Post Risk Warning - A special rectification team led by the chairman has been established to address issues highlighted in the internal control audit report, focusing on areas such as research and development process management and financial management [4]. - The company is conducting internal checks on its management systems and has implemented stricter contract signing processes, requiring multi-department evaluations for new contracts [4]. - Financial processes are being thoroughly reviewed to ensure compliance with accounting standards, including the introduction of a dedicated review process for financial data [5]. - The company is enhancing its internal control operations by revising internal control systems and conducting special checks to ensure effective execution [5]. - Company executives are participating in training organized by regulatory bodies to improve their understanding of securities laws and regulations [6]. - The company is cooperating with the China Securities Regulatory Commission regarding an investigation into alleged information disclosure violations [6]. - Communication with professional accounting firms is ongoing to improve governance and ensure smooth auditing processes for the fiscal year 2025 [6]. - The company is focusing on compliance management and enhancing communication with regulatory authorities to strengthen its risk prevention framework [6].

Core Insights - In 2025, A-share listed companies achieved a new level of high-quality development driven by policy guidance, focusing on governance transparency, innovation efficiency, and normalized returns [1] Governance and Innovation Enhancement - The improvement in governance became a significant driver for high-quality development, with a shift from "passive compliance" to "active value creation" in internal control and ESG practices [2] - By 2025, 99.89% of listed companies disclosed internal control deficiencies, a substantial increase reflecting enhanced regulatory enforcement and corporate compliance awareness [2] - ESG report disclosure reached 99% among A-share companies, with state-owned enterprises achieving 100% coverage, indicating a transition towards proactive integration of ESG into long-term strategies [2] Market Structure Optimization - The dual mechanism of delisting and the expansion of specialized and innovative enterprises led to significant market optimization, with a 44% year-on-year decrease in delisting rates [3] - The number of specialized and innovative enterprises rose to 2,100, directing resources towards high-innovation companies, thereby enhancing overall market vitality [3] - Average R&D intensity for specialized and innovative enterprises reached 8%, significantly higher than non-specialized counterparts, showcasing a clear focus on innovation in sectors like semiconductors and new energy [3] Shareholder Return Mechanism Maturation - In 2025, the willingness and ability of listed companies to return value to investors reached new heights, with total cash dividends amounting to 2.08 trillion yuan and share buybacks totaling 142.84 billion yuan, resulting in a combined return of 2.22 trillion yuan [4] - The trend of normalized and diversified dividends was evident, with companies like Rihua Co. increasing their dividend payout ratio by 19.66 percentage points to 57.71% [4] - The purpose of buybacks became more diverse, with 42% aimed at "market value management" and 38% for "employee stock ownership plans," indicating a mature approach to shareholder returns [4] Market Ecosystem Development - Analysts noted that leading companies are stabilizing investor expectations through substantial returns, reflecting both robust operational performance and a maturing market ecosystem focused on shareholder returns [5] - Trends in dividends included increased frequency, improved quality and transparency, driven by regulatory measures and market dynamics, fostering a virtuous cycle of "dividends—valuation increase—further dividends" [6] - Strong policy support and spontaneous market behavior are creating a new ecosystem characterized by better structure, governance, innovation, and returns [6]

Core Viewpoint - Tianjin Pharmaceutical Industry Co., Ltd. has acknowledged the regulatory issues raised by the Tianjin Securities Regulatory Bureau and has committed to implementing a comprehensive rectification plan to address these concerns and enhance internal controls and compliance awareness [5][15]. Group 1: Meeting and Decision - The 24th meeting of the 9th Board of Directors was held on February 26, 2026, via telecommunication, with all 9 directors participating [1][3]. - The board unanimously approved the rectification report in response to the Tianjin Securities Regulatory Bureau's corrective measures [1][3]. Group 2: Rectification Requirements - The company aims to strictly adhere to relevant regulations, including the "Guidelines for the Governance of Listed Companies" and internal control application guidelines, ensuring thorough investigation and long-term management of identified issues [5][6]. - The rectification goals include resolving issues related to contract management, timely identification of R&D project termination risks, and improving internal control systems [6][15]. Group 3: Main Issues and Rectification Measures - Identified issues include non-standard contract management and delays in recognizing R&D project termination risks, leading to slow recovery of advance payments [7][10]. - Specific rectification measures include revising contract templates to ensure clarity and compliance, enhancing the contract review process, and establishing a risk management mechanism for R&D projects [8][11]. Group 4: Continuous Rectification Plan - The company has developed a continuous rectification plan to reinforce compliance education, enhance internal control systems, and optimize fund management processes [13][14]. - Ongoing training and supervision will be implemented to ensure adherence to regulations and improve governance standards [13][14]. Group 5: Commitment to Rectification - The board and management have expressed a strong commitment to addressing the issues highlighted by the regulatory authority and ensuring that all rectification measures are completed on time and effectively [15].

Core Viewpoint - Financial Street Securities has faced multiple regulatory fines due to compliance issues, primarily related to "flying orders," private fund sales violations, and internal control deficiencies during the period from December 2025 to January 2026 [1] Company Structure and Governance - Regulatory authorities have identified significant gaps in the monitoring of branch offices and employee compliance management at Financial Street Securities. Employees in various locations, including Shanghai, Inner Mongolia, and Guangdong, have been found promoting third-party platform products without authorization and even organizing investors to funnel funds into personal accounts for private fund purchases [2] - The Inner Mongolia Securities Regulatory Bureau criticized the company for inadequate internal controls and ineffective management of employee behavior in its December 31, 2025, fine [2] Policy and Regulation - Some employees failed to use the company's standardized promotional materials, which contained misleading statements and concealed risks. The Guangdong Securities Regulatory Bureau also discovered that certain branches made promises of capital protection and guaranteed returns, indicating a failure to implement effective compliance reviews and risk prevention mechanisms [3] Company Status - Financial Street Securities' wholly-owned investment banking subsidiary, Hengtai Changcai Securities, was penalized in 2025 for risk management issues in its bond business, and both investment banking and bond operations were rated as Class C in terms of professional quality evaluation, reflecting below-industry standards. The recent fines further expose the persistent compliance issues at the group level [4] Industry Policy and Environment - In recent years, regulatory authorities have adopted a dual accountability model targeting both institutions and individuals for violations related to "flying orders" and private fund sales, with increasing penalties. The concentrated display of Financial Street Securities' violations under heightened regulatory scrutiny has led to multiple accountability actions from various securities regulatory bureaus in a short period [5]

Core Viewpoint - Tianji Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure regulations, but the company asserts that its production and operational activities remain normal and unaffected by the investigation [2][4]. Group 1: Regulatory Actions - The CSRC has decided to initiate a case against Tianji Co., Ltd. due to issues related to improper goodwill impairment testing, inaccurate financial accounting, and non-compliance with information disclosure regulations [2][4]. - The Guangdong Regulatory Bureau issued an administrative regulatory decision, citing the company's failure to adhere to the "Management Measures for Information Disclosure of Listed Companies" [5]. - The Shenzhen Stock Exchange has also issued a regulatory letter to Tianji Co., Ltd. regarding the same violations [5]. Group 2: Company Response - Tianji Co., Ltd. has expressed its commitment to cooperate with the CSRC and to rectify the identified issues by implementing corrective measures and submitting a written report to the regulatory authorities [6]. - The company plans to enhance its understanding of relevant laws and regulations, improve its internal control systems, and elevate the quality of its information disclosure to protect the interests of shareholders [6]. Group 3: Financial and Shareholder Information - As of February 11, the stock price of Tianji Co., Ltd. was reported at 43.96 yuan per share, with a total market capitalization of 22 billion yuan [7]. - As of January 30, the company had over 180,000 shareholders, reflecting a 2.02% increase in the number of shareholders compared to the previous period [9][10].